Wall Street analyst estimates for Edgewise Therapeutics, Inc. (EWTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial.
Consensus price target
$53.10 (+37% vs price $38.87)
between $36.00 and $66.00 · 3 targets published in the last quarter
Closing price, Nov 5
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $2.3M | $1.2M – $3.7M | -$2.05 | 9 |
| 2027E | $27.3M | $11.9M – $47.4M | -$1.71 | 10 |
| 2028E | $89.4M | $47.9M – $144M | -$1.81 | 10 |
Figures in USD · consensus as of November 5, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 11 |
| Avg rating (−2 sell to +2 buy) | 0.82 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.52 | ||
| 2026-08-06 | $-0.53 | $-0.47 | -13.3% |
| 2026-05-07 | $-0.46 | $-0.50 | +8.0% |
| 2026-02-26 | $-0.47 | $-0.43 | -9.3% |
| 2025-11-06 | $-0.39 | $-0.40 | +2.5% |
| 2025-08-07 | $-0.34 | $-0.42 | +19.0% |
| 2025-05-08 | $-0.43 | $-0.45 | +4.4% |
| 2025-03-03 | $-0.42 | $-0.39 | -7.7% |
Valuation Ratios
| P/E Ratio | 4.75 |
| Price / Book | 2.59 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $123,000 | $185,000 | 0 | 0 | 0 | 0 | $2.3M |
| Gross Profit | -$123,000 | -$185,000 | 0 | 0 | 0 | 0 | -$2.3M |
| Research & Development | $8.6M | $14.8M | $32.2M | $54.0M | $90.9M | $127.0M | $151.4M |
| Selling, General & Admin | $1.3M | $2.2M | $11.0M | $17.6M | $23.5M | $31.9M | $40.0M |
| Operating Expenses | $9.9M | $17.0M | $43.2M | $71.7M | $114.4M | $158.8M | $189.1M |
| Operating Income | -$9.9M | -$17.2M | -$43.2M | -$71.7M | -$114.4M | -$158.8M | -$191.4M |
| EBITDA | -$9.8M | -$17.0M | -$42.5M | -$63.1M | -$98.4M | -$131.5M | -$165.5M |
| Interest Expense | 0 | 0 | 0 | $4.0M | 0 | 0 | 0 |
| Pre-tax Income | -$9.7M | -$17.1M | -$42.8M | -$67.6M | -$100.2M | -$133.8M | -$167.8M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$9.5M | -$17.1M | -$42.8M | -$67.6M | -$100.2M | -$133.8M | -$167.8M |
| EPS | -$0.19 | -$0.35 | -$0.86 | -$1.26 | -$1.57 | -$1.45 | -$1.63 |
| EPS (Diluted) | -$0.19 | -$0.35 | -$0.86 | -$1.26 | -$1.57 | -$1.45 | -$1.63 |
| Shares Outstanding (Diluted) | 49.2 M | 49.2 M | 49.5 M | 53.6 M | 63.7 M | 92.4 M | 102.9 M |
Price
| Price | $38.87 (closing price, November 5, 2026) |
| Market Cap | $4.2B |
| Exchange | NASDAQ |
| Country | US |
Related companies: PTCT · DYN · VRTX · 0QZU.L · MRNA · REGN · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of EWTX: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks